High-throughput organo-on-pillar (high-TOP) array system for three-dimensional ex vivo drug testing.

[1]  Anders B. Dohlman,et al.  Patient-derived micro-organospheres enable clinical precision oncology. , 2022, Cell stem cell.

[2]  A. Oza,et al.  Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. , 2021, The Lancet. Oncology.

[3]  E. Gendaszewska-Darmach,et al.  Nanocellulose-Based Scaffolds for Chondrogenic Differentiation and Expansion , 2021, Frontiers in Bioengineering and Biotechnology.

[4]  Dong Woo Lee,et al.  3D tumor spheroid microarray for high-throughput, high-content natural killer cell-mediated cytotoxicity , 2021, Communications Biology.

[5]  Z. Dong,et al.  Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy , 2021, Molecular cancer.

[6]  Shanshan Cheng,et al.  Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer. , 2021, Biochimica et biophysica acta. Reviews on cancer.

[7]  Yu Zhu,et al.  An Automated Organoid Platform with Inter-organoid Homogeneity and Inter-patient Heterogeneity , 2020, Cell reports. Medicine.

[8]  H. Clevers,et al.  Establishment of patient-derived cancer organoids for drug-screening applications , 2020, Nature Protocols.

[9]  G. Ho,et al.  Palbociclib in the treatment of recurrent ovarian cancer , 2020, Gynecologic oncology reports.

[10]  V. Tang.  Collagen, stiffness, and adhesion: the evolutionary basis of vertebrate mechanobiology , 2020, Molecular biology of the cell.

[11]  D. Aoki,et al.  Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing , 2020, Scientific Reports.

[12]  A. Tesei,et al.  Modeling neoplastic disease with spheroids and organoids , 2020, Journal of Hematology & Oncology.

[13]  Matthias P. Lutolf,et al.  High-throughput automated organoid culture via stem-cell aggregation in microcavity arrays , 2020, Nature Biomedical Engineering.

[14]  W. Murphy,et al.  Synthetic alternatives to Matrigel , 2020, Nature Reviews Materials.

[15]  Jeong-Won Lee,et al.  Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer , 2020, Scientific Reports.

[16]  G. Lou,et al.  Organoid of ovarian cancer: genomic analysis and drug screening , 2020, Clinical and Translational Oncology.

[17]  M. He,et al.  Doxorubicin Induces Endotheliotoxicity and Mitochondrial Dysfunction via ROS/eNOS/NO Pathway , 2020, Frontiers in Pharmacology.

[18]  Moo-Yeal Lee,et al.  High-content imaging of 3D-cultured neural stem cells on a 384-pillar plate for the assessment of cytotoxicity. , 2020, Toxicology in vitro : an international journal published in association with BIBRA.

[19]  A. Drilon,et al.  Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. , 2019, The Lancet. Oncology.

[20]  Jason K. Sa,et al.  Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers , 2019, Genome Biology.

[21]  F. Meric-Bernstam,et al.  Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study , 2019, Oncotarget.

[22]  Soojung Hahn,et al.  Development of Collagen-Based 3D Matrix for Gastrointestinal Tract-Derived Organoid Culture , 2019, Stem cells international.

[23]  H. Salehiniya,et al.  Ovarian cancer in the world: epidemiology and risk factors , 2019, International journal of women's health.

[24]  Jose Espejo Valle-Inclan,et al.  An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity , 2019, Nature Medicine.

[25]  Toshio Takahashi,et al.  Organoids for Drug Discovery and Personalized Medicine. , 2019, Annual review of pharmacology and toxicology.

[26]  Massimo Broggini,et al.  Platinum Resistance in Ovarian Cancer: Role of DNA Repair , 2019, Cancers.

[27]  J. Nissink,et al.  Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent. , 2018, Journal of medicinal chemistry.

[28]  Kyoung-Mee Kim,et al.  Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy , 2018, Nature Genetics.

[29]  Kongming Wu,et al.  Organoid technology and applications in cancer research , 2018, Journal of Hematology & Oncology.

[30]  Moo-Yeal Lee,et al.  High-throughput metabolism-induced toxicity assays demonstrated on a 384-pillar plate , 2018, Archives of Toxicology.

[31]  Hans Clevers,et al.  Organoids in cancer research , 2018, Nature Reviews Cancer.

[32]  Kriengsak Lirdprapamongkol,et al.  Mechanism of ECM-induced dormancy and chemoresistance in A549 human lung carcinoma cells. , 2018, Oncology reports.

[33]  Jin Woo Choi,et al.  Phosphorylation of caspase-9 at Thr125 directs paclitaxel resistance in ovarian cancer , 2017, Oncotarget.

[34]  M. Sporn,et al.  Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer. , 2017, Cancer letters.

[35]  Catarina Brito,et al.  Drug screening in 3D in vitro tumor models: overcoming current pitfalls of efficacy read‐outs , 2017, Biotechnology journal.

[36]  Nayoung Kim,et al.  Helicobacter pylori Eradication Downregulates Cellular Inhibitor of Apoptosis Protein 2 in Gastric Carcinogenesis , 2016, Gut and liver.

[37]  Jens M. Kelm,et al.  In vitro 3D Spheroids and Microtissues: ATP-based Cell Viability and Toxicity Assays , 2016 .

[38]  Jun Liu,et al.  A novel AKT inhibitor, AZD5363, inhibits phosphorylation of AKT downstream molecules, and activates phosphorylation of mTOR and SMG-1 dependent on the liver cancer cell type , 2016, Oncology letters.

[39]  ChuHee Lee,et al.  Overexpression of Tyro3 receptor tyrosine kinase leads to the acquisition of taxol resistance in ovarian cancer cells. , 2015, Molecular medicine reports.

[40]  Ayala Hubert,et al.  Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Donna D. Zhang,et al.  Induction of autophagy contributes to cisplatin resistance in human ovarian cancer cells , 2014, Molecular medicine reports.

[42]  Allan Wu,et al.  AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. , 2014, Blood.

[43]  M. Zaman,et al.  Embedded multicellular spheroids as a biomimetic 3D cancer model for evaluating drug and drug-device combinations. , 2014, Biomaterials.

[44]  J. Cragun,et al.  PAX8: a sensitive and specific marker to identify cancer cells of ovarian origin for patients prior to neoadjuvant chemotherapy , 2013, Journal of Hematology & Oncology.

[45]  J. Camm,et al.  A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors , 2013, Clinical Cancer Research.

[46]  S. Iturria,et al.  HTS Assay Validation , 2012 .

[47]  I. Shih,et al.  Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis , 2011, Modern Pathology.

[48]  A. D. Van den Abbeele,et al.  Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. , 2010, AJR. American journal of roentgenology.

[49]  A. El-Osta,et al.  γH2AX: a sensitive molecular marker of DNA damage and repair , 2010, Leukemia.

[50]  Genee Y. Lee,et al.  Three-dimensional culture models of normal and malignant breast epithelial cells , 2007, Nature Methods.

[51]  Chun-Min Lo,et al.  Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin. , 2007, Neoplasia.

[52]  Liz Y. Han,et al.  Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. , 2006, Cancer research.

[53]  J. Ledermann,et al.  Management of platinum-sensitive recurrent ovarian cancer. , 2006, Seminars in oncology.

[54]  Kunle Odunsi,et al.  Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer. , 2006, Gynecologic oncology.

[55]  H. Kleinman,et al.  Matrigel: basement membrane matrix with biological activity. , 2005, Seminars in cancer biology.

[56]  C. Palii,et al.  Novel fluorescence assay using calcein‐AM for the determination of human erythrocyte viability and aging , 2005, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[57]  C. Bokemeyer,et al.  Topotecan – A Novel Topoisomerase I Inhibitor: Pharmacology and Clinical Experience , 1999, Oncology.

[58]  John J. Peterson,et al.  Estimation of Confidence Intervals for Area Under the Curve from Destructively Obtained Pharmacokinetic Data , 1998, Journal of Pharmacokinetics and Biopharmaceutics.

[59]  M. Christian,et al.  Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  J. Moylan,et al.  Doxorubicin acts via mitochondrial ROS to stimulate catabolism in C2C12 myotubes. , 2012, American journal of physiology. Cell physiology.

[61]  J. Chovancová,et al.  Enhanced sensitivity of human ovarian carcinoma cell lines A2780 and A2780/CP to the combination of cisplatin and synthetic isothiocyanate ethyl 4-isothiocyanatobutanoate. , 2005, Neoplasma.

[62]  F. A. Barile,et al.  In VitroCytotoxicity Testing with Fluorescence-Based Assays in Cultured Human Lung and Dermal Cells , 2004, Cell Biology and Toxicology.

[63]  J. Neijt,et al.  First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer--a new standard of care? , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[64]  B. de Kruijff,et al.  The influence of poly(L-lysine) on phospholipid polymorphism. Evidence that electrostatic polypeptide-phospholipid interactions can modulate bilayer/non-bilayer transitions. , 1980, Biochimica et biophysica acta.